MRK
Merck & Co., Inc.
NYSE: MRK · Rahway, NJ · Healthcare
$131.07+0.59 (+0.45%)Closed
Market Cap$323.72B
Cash$5.70Bmost recent
Runwayprofitable
P/E (TTM)18.0EPS $7.28
52-Wk Range$75.59 – $131.07
Avg Volume11.9M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$131.07+11.3%
Pipeline

Drug candidates sponsored by Merck & · ClinicalTrials.gov

89 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Infliximab (Remicade)
Arthritis, Rheumatoid
Completed
2004-04-01past
1
Phase 4Efalizumab
Candidates for Systemic Therapy for Psoriasis+2 more
Completed
2006-05-30past
2
Phase 4Unnamed
Observation of Neuromuscular Block
Completed
2012-05past
1
Phase 4Unnamed
Infertility
Terminated
2019-11-20past
1
Phase 4Pembrolizumab
Squamous Cell Carcinoma of Head and Neck+5 more
Recruiting
2026-10-29
6
Phase 3MK0966 / Duration of Treatment: 1 Days
Pain, Postoperative Arthroscopy
Completed
2003-02past
1
Phase 3MK0767
Diabetes Mellitus, Type 2
Terminated
2003-11past
1
Phase 3MK0869, aprepitant
Major Depressive Disorder
Completed
2003-12-22past
2
Phase 3MK0826, ertapenem sodium / Duration of Treatment: 14 Days
Sepsis
Completed
2005-12past
1
Phase 3Placebo
Bowel Dysfunction+1 more
Completed
2006-06past
1
Phase 3Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)
Neoplasms, Glandular and Epithelial+4 more
Completed
2007-05past
1
Phase 3Comparator: odanacatib
Breast Cancer
Withdrawn
2008-09past
1
Phase 3Infliximab Increased Frequency
Rheumatoid Arthritis
Terminated
2008-10past
1
Phase 3MK-0518
HIV Infections
Completed
2009-05past
1
Phase 3Cetuximab + concomitant boost radiotherapy
Squamous Cell Carcinoma of the Head and Neck
Completed
2010-09past
1
Phase 3Pegylated interferon alfa-2b
Hepatitis C
Completed
2010-12past
1
Phase 3Suvorexant High Dose (HD)
Primary Insomnia
Completed
2011-09-09past
1
Phase 3Ertugliflozin 5 mg
Type 2 Diabetes Mellitus
Completed
2016-09-28past
1
Phase 3V212
Herpes Zoster
Completed
2017-04-11past
1
Phase 3Pembrolizumab 200 mg
Non-Small-Cell Lung Carcinoma
Completed
2017-11-08past
1
Phase 3LV305
Synovial Sarcoma+4 more
Terminated
2018-11-20past
1
Phase 3Ertugliflozin
Type 2 Diabetes Mellitus
Completed
2019-12-27past
1
Phase 3Lenvatinib
Endometrial Neoplasms+1 more
Completed
2023-10-11past
2
Phase 3Letermovir
Cytomegalovirus Infection
Completed
2024-04-18past
1
Phase 3Bomedemstat
Essential Thrombocythemia
Active, not recruiting
2027-09-28
1
Phase 3Belzutifan
Carcinoma, Renal Cell+1 more
Active, not recruiting
2034-01-02
2
Phase 3MK0217, alendronate sodium / Duration of Treatment: 1 Month
Osteoporosis
Completed—1
Phase 2diquafosol tetrasodium (INS365) ophthalmic solution
Dry Eye Disease
Completed
2000-07past
1
Phase 2MK0777
Anxiety Disorders
Completed
2003-02past
1
Phase 2denufosol tetrasodium (INS37217)
Cystic Fibrosis
Completed
2006-09past
1
Phase 2Recombinant human follicle stimulating hormone (r-hFSH)
Infertility+1 more
Completed
2006-11-15past
1
Phase 2MK0633
Atherosclerosis
Completed
2006-12past
1
Phase 2alvimopan
Cancer+1 more
Completed
2007-04past
1
Phase 2Temozolomide and radiotherapy
Carcinoma, Non-Small-Cell Lung
Terminated
2008-01-16past
1
Phase 2MK0249
Paranoid Schizophrenia
Completed
2008-10past
1
Phase 2Preladenant
Parkinson Disease+4 more
Completed
2008-10-05past
1
Phase 2Comparator: A: Pregabalin
Painful Diabetic Neuropathy
Withdrawn
2009-08past
1
Phase 2Temozolomide
Metastases of Central Nervous System+5 more
Completed
2010-06-30past
2
Phase 2IDX184
Hepatitis C, Chronic
Completed
2013-03past
1
Phase 2Dalantercept
Squamous Cell Carcinoma of the Head and Neck
Completed
2015-06past
1
Phase 2CD101 Vaginal Gel (3%)
Candidiasis, Vulvovaginal+4 more
Completed
2016-11-23past
1
Phase 2Raltegravir (MK-0518)
HIV Infections
Terminated
2017-07-10past
1
Phase 1Tivantinib
Advanced Solid Tumors
Completed
2019-01-14past
1
Phase 2Daptomycin for Injection
Bacteremia+2 more
Completed
2020-04-07past
1
Phase 2Navarixin
Solid Tumors+3 more
Completed
2021-05-19past
1
Phase 1HPN424 Fixed IV 1.3 to 150 ng/kg
Advanced Prostate Cancer
Terminated
2023-02-27past
1
Phase 2Tulisokibart
Radiographic Axial Spondyloarthritis
Recruiting
2027-06-15
1
Phase 2Sotatercept
Pulmonary Arterial Hypertension
Active, not recruiting
2028-06-16
1
Phase 2MK-2214
Early Alzheimer's Disease
Recruiting
2029-04-30
1
Phase 1MK-1045
Lymphoma, Non-Hodgkin+2 more
Recruiting
2030-07-01
1
Phase 2Indinavir sulfate
HIV Infections
Unknown—1
Phase 1MK0457
Chronic Myelogenous Leukemia in Blast Crisis+3 more
Completed
2008-05past
1
Phase 1TR-701 600mg
Healthy
Completed
2008-05-15past
1
Phase 1sitagliptin phosphate
Type 2 Diabetes Mellitus
Completed
2009-04-30past
1
Phase 1MK-3281
Hepatitis C
Completed
2009-12-22past
1
Phase 1Ertugliflozin 2 mg single dose
Diabetes Mellitus, Type 2+1 more
Completed
2010-04-07past
1
Phase 1EMD 525797
Prostate Cancer+1 more
Completed
2010-09past
1
Phase 1anacetrapib
Dyslipidemia
Completed
2011-06past
1
Phase 1MK-2206
Locally Advanced Tumors+3 more
Completed
2011-07-11past
1
Phase 1V950
Alzheimer Disease
Completed
2012-01past
1
Phase 1Low-Dose MK-8351
Asthma
Withdrawn
2014-04past
1
Phase 1Oral dispersible tablet of praziquantel (ODT-PZQ)
Healthy
Completed
2015-01past
1
Phase 1MK-7680
Hepatitis C
Completed
2015-02past
1
Phase 1Ulonivirine
HIV-1 Infection
Completed
2015-07-16past
1
Phase 1MK-3682B
Hepatitis C
Completed
2016-08-26past
1
Phase 1Gefapixant
Renal Insufficiency
Completed
2017-09-03past
1
Phase 1Bisoprolol-Amlodipine FDC
Healthy
Completed
2017-09-09past
1
Phase 1MK-1966
Neoplasms, Advanced
Terminated
2018-01-08past
1
Phase 1MK-7252
Pharmacokinetics+1 more
Completed
2018-12-17past
1
Phase 1M5717
Healthy
Completed
2019-06-14past
1
Phase 1MK-3402
Renal Impairment
Terminated
2021-04-15past
1
Phase 1Evobrutinib
Healthy
Completed
2022-07-18past
1
Phase 1Molnupiravir
Renal Impairment
Completed
2023-02-04past
1
Phase 1MK-6194
Healthy
Completed
2023-07-13past
1
Phase 1Saline placebo
Healthy
Completed
2023-07-14past
1
Phase 1Nemtabrutinib
Mature B-cell Neoplasms+1 more
Completed
2026-05-04past
2
Phase 1M9140
Solid Tumors+1 more
Active, not recruiting
2026-09-30
1
N/AInfliximab
Rheumatoid Arthritis
Completed
2008-06past
1
N/APegylated Liposomal Doxorubicin
Breast Neoplasm
Completed
2010-06past
1
N/AUnnamed
Neuromuscular Blockade
Completed
2010-11past
1
N/AUnnamed
Infertility
Completed
2011-02past
1
N/APosaconazole or alternative fungal treatment
Mycoses
Withdrawn
2011-05past
1
N/AUnnamed
Alzheimer's Disease
Completed
2011-09past
1
N/APeginterferon alfa-2b
Hepatitis C+1 more
Completed
2011-10past
1
N/AUnnamed
Dyslipidemias+4 more
Completed
2012-12past
1
N/AUnnamed
Human Immunodeficiency Virus
Terminated
2013-10-31past
1
N/ACetuximab
Head and Neck Cancer
Completed
2014-07past
1
N/APergoveris®
Infertility
Completed
2018-05-10past
1
N/ANirogacestat (Gamma Secretase Inhibitor)
Desmoid Tumor+1 more
Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for MRK. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.